Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
Bagshawe KD, Sharma SK, Begent RH. Bagshawe KD, et al. Among authors: begent rh. Expert Opin Biol Ther. 2004 Nov;4(11):1777-89. doi: 10.1517/14712598.4.11.1777. Expert Opin Biol Ther. 2004. PMID: 15500406 Review.
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH. Francis RJ, et al. Among authors: begent rh. Br J Cancer. 2002 Sep 9;87(6):600-7. doi: 10.1038/sj.bjc.6600517. Br J Cancer. 2002. PMID: 12237768 Free PMC article. Clinical Trial.
Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).
Francis RJ, Mather SJ, Chester K, Sharma SK, Bhatia J, Pedley RB, Waibel R, Green AJ, Begent RH. Francis RJ, et al. Among authors: begent rh. Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1090-6. doi: 10.1007/s00259-004-1474-4. Epub 2004 Mar 17. Eur J Nucl Med Mol Imaging. 2004. PMID: 15029458
Advances in antibody-directed enzyme prodrug therapy.
Sharma SK, Bagshawe KD, Begent RH. Sharma SK, et al. Among authors: begent rh. Curr Opin Investig Drugs. 2005 Jun;6(6):611-5. Curr Opin Investig Drugs. 2005. PMID: 15997480 Review.
A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA, Begent RH. Mayer A, et al. Among authors: begent rh. Clin Cancer Res. 2006 Nov 1;12(21):6509-16. doi: 10.1158/1078-0432.CCR-06-0769. Clin Cancer Res. 2006. PMID: 17085666 Clinical Trial.
Engineering antibodies for clinical applications in cancer.
Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent R. Chester K, et al. Tumour Biol. 2004 Jan-Apr;25(1-2):91-8. doi: 10.1159/000077727. Tumour Biol. 2004. PMID: 15192316 Review.
From laboratory to Phase I/II cancer trials with recombinant biotherapeutics.
Tolner B, Smith L, Hillyer T, Bhatia J, Beckett P, Robson L, Sharma SK, Griffin N, Vervecken W, Contreras R, Pedley RB, Begent RH, Chester KA. Tolner B, et al. Among authors: begent rh. Eur J Cancer. 2007 Nov;43(17):2515-22. doi: 10.1016/j.ejca.2007.08.027. Epub 2007 Oct 22. Eur J Cancer. 2007. PMID: 17933516 Review.
222 results